General analysis of breast cancer patients tested for BRCA mutations and evaluation of acute radiotherapy toxicity.

Northern clinics of Istanbul Pub Date : 2024-08-01 eCollection Date: 2024-01-01 DOI:10.14744/nci.2023.93196
Sule Karabulut Gul, Huseyin Tepetam, Berrin Benli Yavuz, Ozge Kandemir Gursel, Ayse Altinok, Irem Yuksel, Omar Alomari, Banu Atalar, Ilknur Bilkay Gorken
{"title":"General analysis of breast cancer patients tested for BRCA mutations and evaluation of acute radiotherapy toxicity.","authors":"Sule Karabulut Gul, Huseyin Tepetam, Berrin Benli Yavuz, Ozge Kandemir Gursel, Ayse Altinok, Irem Yuksel, Omar Alomari, Banu Atalar, Ilknur Bilkay Gorken","doi":"10.14744/nci.2023.93196","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of our study is to evaluate breast cancer patients with BRCA1 or BRCA2 gene mutations and compare them with patients without these mutations. Specifically, we aim to assess the acute side effects of radiotherapy in both groups.</p><p><strong>Methods: </strong>Data were collected from four participating centers, comprising information from 73 patients who underwent known mutation analysis and had complete data. Patients were monitored on a weekly basis throughout their treatment for acute toxicity, which was evaluated using the Radiation Therapy Oncology Group (RTOG) acute toxicity criteria.</p><p><strong>Results: </strong>The median age of the 73 patients included in our study was 43. Among them, 17 had BRCA1-positive mutations and 19 had BRCA2-positive mutations. Invasive ductal carcinoma was present in 67 patients, all of whom underwent surgery. Of the patients, 57 received conventional radiotherapy doses, while 16 received hypofractionated radiotherapy doses. During follow-up, metastasis occurred in three patients. In BRCA-positive patients, those under 40 years of age (p<0.001), with high nodal positivity (p=0.008), grade 2-3 (p=0.022), and lymphovascular invasion (p=0.002) were significantly more frequent compared to BRCA-negative patients (p<0.001). The median survival was 35.8 months. Grade 1 dysphagia developed in seven BRCA-negative patients and four BRCA-positive patients, with no significant difference observed between the two groups (p=0.351). There was also no statistical difference observed in the occurrence of grade 2-3 skin reactions, with 11 BRCA-negative patients and eight BRCA-positive patients experiencing these side effects.</p><p><strong>Conclusion: </strong>Our study supports existing literature by identifying an association between the presence of BRCA mutations and young age, nodal status, grade, and lymphovascular invasion. Additionally, we found no significant difference in the occurrence of radiotherapy toxicity between BRCA-positive and BRCA-negative patients. These findings suggest that radiotherapy can be safely administered to BRCA-positive patients after breast-conserving surgery or mastectomy. Keywords for our study include breast cancer, BRCA mutation, radiotherapy, and side effects.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"11 4","pages":"302-308"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11331201/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Northern clinics of Istanbul","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14744/nci.2023.93196","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The objective of our study is to evaluate breast cancer patients with BRCA1 or BRCA2 gene mutations and compare them with patients without these mutations. Specifically, we aim to assess the acute side effects of radiotherapy in both groups.

Methods: Data were collected from four participating centers, comprising information from 73 patients who underwent known mutation analysis and had complete data. Patients were monitored on a weekly basis throughout their treatment for acute toxicity, which was evaluated using the Radiation Therapy Oncology Group (RTOG) acute toxicity criteria.

Results: The median age of the 73 patients included in our study was 43. Among them, 17 had BRCA1-positive mutations and 19 had BRCA2-positive mutations. Invasive ductal carcinoma was present in 67 patients, all of whom underwent surgery. Of the patients, 57 received conventional radiotherapy doses, while 16 received hypofractionated radiotherapy doses. During follow-up, metastasis occurred in three patients. In BRCA-positive patients, those under 40 years of age (p<0.001), with high nodal positivity (p=0.008), grade 2-3 (p=0.022), and lymphovascular invasion (p=0.002) were significantly more frequent compared to BRCA-negative patients (p<0.001). The median survival was 35.8 months. Grade 1 dysphagia developed in seven BRCA-negative patients and four BRCA-positive patients, with no significant difference observed between the two groups (p=0.351). There was also no statistical difference observed in the occurrence of grade 2-3 skin reactions, with 11 BRCA-negative patients and eight BRCA-positive patients experiencing these side effects.

Conclusion: Our study supports existing literature by identifying an association between the presence of BRCA mutations and young age, nodal status, grade, and lymphovascular invasion. Additionally, we found no significant difference in the occurrence of radiotherapy toxicity between BRCA-positive and BRCA-negative patients. These findings suggest that radiotherapy can be safely administered to BRCA-positive patients after breast-conserving surgery or mastectomy. Keywords for our study include breast cancer, BRCA mutation, radiotherapy, and side effects.

对接受 BRCA 基因突变检测的乳腺癌患者进行总体分析,并评估急性放疗毒性。
研究目的我们的研究目的是评估 BRCA1 或 BRCA2 基因突变的乳腺癌患者,并将他们与没有这些基因突变的患者进行比较。具体而言,我们旨在评估两组患者放疗的急性副作用:方法:我们从四个参与中心收集了数据,其中包括 73 名接受了已知基因突变分析且数据完整的患者的信息。在整个治疗过程中,每周对患者的急性毒性进行监测,并采用放射治疗肿瘤学组(RTOG)急性毒性标准进行评估:73名患者的中位年龄为43岁。其中,17 例 BRCA1 基因突变阳性,19 例 BRCA2 基因突变阳性。67名患者患有浸润性导管癌,全部接受了手术治疗。其中,57名患者接受了常规剂量的放射治疗,16名患者接受了低分量放射治疗。在随访期间,有三名患者发生了转移。在 BRCA 阳性患者中,40 岁以下的患者(pConclusion:我们的研究证实了 BRCA 基因突变与年轻、结节状态、分级和淋巴管侵犯之间的关系,从而为现有文献提供了支持。此外,我们还发现 BRCA 阳性和 BRCA 阴性患者的放疗毒性发生率没有明显差异。这些研究结果表明,BRCA 阳性患者在接受保乳手术或乳房切除术后可以安全地接受放疗。我们研究的关键词包括乳腺癌、BRCA 基因突变、放疗和副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信